Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oprozomib in Hematologic Malignancies
NCT01416428Phase 2Terminated
- Sponsor
- Amgen
- Start
- Oct 2011
- Primary completion
- Aug 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of oprozomib in hematologic malignancy, multiple myeloma (MM), Waldenstrom macroglobulinemia (WM), sponsored by Amgen. Started Oct 2011; status: terminated.
02
Drugs
oprozomib
03
Conditions
hematologic malignancymultiple myeloma (MM)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01416428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416428.